Topotecan

Generic Name: Topotecan

Brand Names: Hycamtin, Potactasol, Topotecan Hospira

Drug Type: Small Molecule

Chemical Formula: C_₂₃H_₂₃N_₃O_₅

CAS Number: 123948-87-8

Unique Ingredient Identifier: 7M7YKX2N15

Background: An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I.

Indication: 用于小细胞肺癌（SCLC）和一线治疗失败的晚期转移性卵巢癌。

Associated Conditions: Acute Myeloid Leukemia, Ewing's Sarcoma, Refractory Neuroblastoma, Metastatic Rhabdomyosarcoma, Recurrent Stage IVB Cervical Cancer, Refractory CNS lymphoma, Refractory CNS malignancy, Refractory, metastatic Ovarian cancer, Relapsed Platinum Sensitive Small Cell Lung Cancer (SCLC)

Associated Therapies: -

Clinical Trials

REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1

Phase 2

Recruiting

Conditions: Ovarian Cancer
Epithelial Ovarian Cancer
Fallopian Tube Cancer
Primary Peritoneal Cancer
Platinum-resistant Ovarian Cancer

Interventions: Drug: Gemcitabine
Drug: Luveltamab tazevibulin
Drug: Pegfilgrastim
Drug: Paclitaxel
Drug: Pegylated liposomal doxorubicin
Drug: Topotecan

First Posted Date: 2023-05-23

Last Posted Date: 2024-08-29

Lead Sponsor: Sutro Biopharma, Inc.

Target Recruit Count: 600

Registration Number: NCT05870748

Locations: 🇺🇸
Texas Oncology, Dallas, Texas, United States
🇺🇸
Ohio State University Center, Columbus, Ohio, United States
🇺🇸
Baptist Health South Florida (BHSF) - Miami Cancer Institute, Miami, Florida, United States

and more 36 locations

Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer

Phase 2

Recruiting

Conditions: Lung Cancer
Small-cell Lung Cancer
Non Small Cell Lung Cancer

Interventions: Drug: Carboplatin
Drug: Pemetrexed
Drug: Paclitaxel
Drug: Nab paclitaxel
Drug: Docetaxel
Drug: Gemcitabine
Drug: Etoposide
Drug: Irinotecan
Drug: Topotecan
Drug: Lurbinectedin

First Posted Date: 2023-04-05

Last Posted Date: 2024-03-26

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 280

Registration Number: NCT05800587

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer

Phase 3

Active, not recruiting

Conditions: Small Cell Lung Cancer (SCLC)

Interventions: Drug: Tarlatamab
Drug: Lurbinectedin
Drug: Topotecan
Drug: Amrubicin

First Posted Date: 2023-02-23

Last Posted Date: 2024-08-28

Lead Sponsor: Amgen

Target Recruit Count: 509

Registration Number: NCT05740566

Locations: 🇧🇪
Vitaz campus Sint-Niklaas Moerland, Sint-Niklaas, Belgium
🇧🇷
Beneficencia Portuguesa de Sao Paulo - Bp, Sao Paulo, São Paulo, Brazil
🇦🇺
Liverpool Hospital, Liverpool, New South Wales, Australia

and more 220 locations

A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 2

Active, not recruiting

Conditions: Neoplasms, Ovarian

Interventions: Drug: MORAb-202
Drug: Paclitaxel
Drug: Pegylated Liposomal Doxorubicin (PLD)
Drug: Topotecan

First Posted Date: 2022-11-14

Last Posted Date: 2024-11-21

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 90

Registration Number: NCT05613088

Locations: 🇦🇺
Local Institution - 0016, Sydney, New South Wales, Australia
🇦🇺
Local Institution - 0017, Waratah, New South Wales, Australia
🇦🇺
Local Institution - 0015, Clayton, Victoria, Australia

and more 57 locations

Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma

Phase 2

Recruiting

Conditions: Medulloblastoma

Interventions: Procedure: Surgical resection
Other: Educational and Media Intervention
Other: SOC, Educational and Media Intervention
Procedure: Ommaya/VPS
Drug: Methotrexate
Drug: Cisplatin
Drug: Vincristine
Drug: Cyclophosphamide
Drug: Carboplatin
Drug: Topotecan
Drug: Pegfilgrastim
Drug: Etoposide
Drug: Filgrastim
Radiation: Irradiation

First Posted Date: 2022-09-10

Last Posted Date: 2024-10-29

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 120

Registration Number: NCT05535166

Locations: 🇺🇸
Primary Children's Hospital, Salt Lake City, Utah, United States
🇺🇸
Lucille Packard Children's Hospital at Stanford University, Palo Alto, California, United States
🇺🇸
Orlando Health Arnold Palmer Hospital for Children, Orlando, Florida, United States

and more 7 locations

Targeting Pediatric Brain Tumors and Relapsed/Refractory Solid Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i)

Phase 1

Recruiting

Conditions: Pediatric Brain Tumor
Pediatric Solid Tumor

Interventions: Drug: Dapagliflozin
Drug: Carmustine
Drug: Topotecan
Drug: Cyclophosphamide

First Posted Date: 2022-08-30

Last Posted Date: 2024-12-19

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 20

Registration Number: NCT05521984

Locations: 🇺🇸
Washington University School of Medicine/St. Louis Children's Hospital, Saint Louis, Missouri, United States

Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors

Phase 1

Recruiting

Conditions: Neuroblastoma

Interventions: Drug: Topotecan
Drug: Temozolomide
Drug: Ribociclib

First Posted Date: 2022-06-23

Last Posted Date: 2024-11-15

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 231

Registration Number: NCT05429502

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
St Jude s Childrens Research Hospital, Memphis, Tennessee, United States
🇺🇸
Cohen Children's Medical Center of New York, New Hyde Park, New York, United States

and more 1 locations

Allogeneic Hematopoietic Stem Cell Transplantation for 4/M Neuroblastoma

Phase 2

Not yet recruiting

Conditions: Neuroblastoma

Interventions: Drug: Anti Thymocyte Globulin
Drug: Fludarabine
Drug: Cyclophosphamide injection
Drug: Topotecan
Drug: Melphalan
Drug: Thiotepa
Drug: Busulfan
Drug: Cyclosporine
Drug: Tacrolimus
Drug: Mycophenolate Mofetil
Drug: Methotrexate

First Posted Date: 2022-03-31

Last Posted Date: 2022-07-01

Lead Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Target Recruit Count: 64

Registration Number: NCT05303727

Locations: 🇨🇳
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China

Berzosertib Human Mass Balance Study (DDRiver Solid Tumors 208)

Phase 1

Completed

Conditions: Advanced Solid Tumor

Interventions: Drug: [14C]Berzosertib
Drug: Berzosertib
Drug: Topotecan

First Posted Date: 2022-02-18

Last Posted Date: 2024-11-22

Lead Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Target Recruit Count: 6

Registration Number: NCT05246111

Locations: 🇭🇺
Magyar Honvédség Egészségügyi Központ, Podmaniczky utcai telephely, Onkológiai Osztály, Budapest, Hungary
🇭🇺
PRA Magyarország Kft. Fázis I-es Klinikai Farmakológiai Vizsgálóhely, Budapest, Hungary

Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)

Phase 3

Recruiting

Conditions: Relapsed Small Cell Lung Cancer

Interventions: Drug: Lurbinectedin
Drug: Irinotecan
Drug: Topotecan

First Posted Date: 2021-12-10

Last Posted Date: 2024-08-02

Lead Sponsor: PharmaMar

Target Recruit Count: 705

Registration Number: NCT05153239

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇨🇱
Clinical Research Chile SpA, Valdivia, Los Ríos, Chile
🇨🇭
University Hospital Basel, Basel, Switzerland

and more 209 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy